Human interleukin-2
- Generic Name
- Human interleukin-2
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- FNO32LO217
- Background
Human interleukin-2 is under investigation in clinical trial NCT03475134 (TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in mMEL).
- Associated Conditions
- -
- Associated Therapies
- -
CIML NK Cells With Venetoclax for AML
Phase 1
Active, not recruiting
- Conditions
- Acute Myeloid LeukemiaAcute Myeloid Leukemia RecurrentLeukemia, MyeloidLeukemia
- Interventions
- Biological: Cytokine-Induced Memory-like Natural Killer CellsBiological: Interleukin-2Drug: Venetoclax
- First Posted Date
- 2023-12-01
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 10
- Registration Number
- NCT06152809
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath